Wearable Devices and Biomarkers Project (Healthiomics)
Part of paid clinical trials in San Diego, California.
- Sponsor
- CureScience
- Study ID
- NCT05106725
- Status
- Recruiting
Conditions
- Brain Cancer
- Neurological Cancer
- Neurological Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.
Key Dates
- Start date
- Oct 11, 2021
- Status verified
- Aug 2024
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 3,500 participants (estimated)
Arms
- Arm: Neurological patientsThis cohort will include patients having been diagnosed with a neurological condition.
- Arm: ControlThis cohort will include patients who have not been diagnosed with a neurological disorder.
Primary Outcome Measure
Specimen and data storage [ Time Frame: 4 years ]
Central Contacts
- Amanda Wilburn8588002873
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| CureScience Institute | San Diego | California | 92121 | Shashaanka Ashili, PhD Feng Lin, MD PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Diego, CA
Related Studies
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruiting · Adela, Inc · Duarte, California
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPHASE2 · Recruiting · Black Diamond Therapeutics, Inc. · Springdale, Arkansas
- Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersRecruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland